NICE:TASENICE Ltd. Analysis
Data as of 2026-03-11 - not real-time
$120.41
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
NICE Ltd. trades at $120.40, well below its DCF‑derived fair value of $158.65, implying roughly a 28% upside and positioning the stock as undervalued. The company’s forward PE of 9.68 and current PE of 12.45 are dramatically lower than the software industry average PE of 37, underscoring a strong value case. Margins remain healthy with a gross margin of 66% and operating margin of 22%, while ROE sits at 16%, indicating efficient capital use. Technicals are supportive: the price is above both the 20‑day (115.3) and 50‑day (114.1) SMAs, the MACD histogram is positive and the signal is bullish, and the RSI of 55 suggests momentum is neither overbought nor oversold. However, volume is on a decreasing trend, which tempers short‑term enthusiasm. Recent news of new AI‑driven risk tools from the Actimize and Cognigy units reinforces the long‑term growth narrative, especially in the high‑margin financial‑crime compliance segment.
The stock’s beta of ~0.85 and 30‑day volatility of 61% point to moderate market sensitivity, while a solid balance sheet—$417 M cash versus $88 M debt—provides a cushion against downturns. Analysts’ consensus is a “Buy” with a median target of $150, further validating upside potential. Given the blend of attractive valuation, robust fundamentals, and strategic AI expansion, the investment case is compelling across horizons, though liquidity concerns from declining volume merit monitoring.
The stock’s beta of ~0.85 and 30‑day volatility of 61% point to moderate market sensitivity, while a solid balance sheet—$417 M cash versus $88 M debt—provides a cushion against downturns. Analysts’ consensus is a “Buy” with a median target of $150, further validating upside potential. Given the blend of attractive valuation, robust fundamentals, and strategic AI expansion, the investment case is compelling across horizons, though liquidity concerns from declining volume merit monitoring.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- Substantial valuation gap to DCF fair value
- Decreasing volume introduces short‑term execution risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong cash flow generation and low debt
- Analyst consensus buy with median target $150
- Revenue growth of ~9% and expanding AI‑driven SaaS offerings
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strategic launch of AI risk‑management platforms
- High‑margin recurring revenue from financial‑crime compliance
- Global customer base reducing reliance on any single geography
Key Metrics & Analysis
Financial Health
Revenue Growth9.00%
Profit Margin20.78%
P/E Ratio12.5
ROE16.37%
ROA7.87%
Debt/Equity2.29
P/B Ratio1.9
Op. Cash Flow$716.5M
Free Cash Flow$457.3M
Industry P/E37.0
Technical Analysis
TrendNeutral
RSI54.8
Support$94.65
Resistance$135.55
MA 20$115.31
MA 50$114.07
MA 200$134.53
MACDBullish
VolumeDecreasing
Fear & Greed Index77.93
Valuation
Fair Value$158.65
Target Price$154.27
Upside/Downside28.12%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.85
Volatility60.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.